Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice

Clinical Rheumatology

Volumn 37, Issue 5, 2018, Pages 1189-1197

  Versteeg, G A ^a,b   Steunebrink, L M M ^a,b   Vonkeman, H E ^a,b   ten Klooster, P M ^b   van der Bijl, A E ^c   van de Laar, M A F J ^a,b  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b UNIVERSITY OF TWENTE   (Netherlands)

^c ISALA HOSPITAL   (Netherlands)

Author keywords

Daily clinical practice; Drug free sustained remission; Implementation; Rheumatoid arthritis; Treat to target

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; DAS28; DISABILITY; DISEASE ACTIVITY; DRUG DOSE INCREASE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MALE; MIDDLE AGED; MONOTHERAPY; OBSERVATIONAL STUDY; PATIENT-REPORTED OUTCOME; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; RHEUMATOID ARTHRITIS; SHORT FORM 36; AGED; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; HEALTH STATUS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; QUALITY OF LIFE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SULFASALAZINE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85045051163     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-017-3962-5     Document Type: Article

References (37)

1. Ma MHY, Scott IC, Kingsley GH, Scott DL (2010) Remission in early rheumatoid arthritis. J Rheumatol 37(7):1444–1453. 10.3899/jrheum.091131
2. Vermeer M, Kuper HH, Hoekstra M, Haagsma CJ, Posthumus MD, Brus HLM, van Riel PLCM, van de Laar MAFJ (2011) Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch rheumatoid arthritis monitoring remission induction cohort study. Arthritis Rheum 63(10):2865–2872. 10.1002/art.30494
3. van den Broek M, Huizinga TWJ, Dijkmans BAC, Allaart CF (2011) Drug-free remission: is it already possible? Curr Opin Rheumatol 23(3):266–272. 10.1097/BOR.0b013e32834563e3
4. Nagy G, van Vollenhoven RF (2015) Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now? Arthritis Res Ther 17(1):181. 10.1186/s13075-015-0707-1
5. Grigor C, Capell H, Stirling A, et al (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. 364:263–269
6. Markusse IM, Dirven L, Gerards AH, van Groenendael JHLM, Ronday HK, Kerstens PJSM, Lems WF, Huizinga TWJ, Allaart CF (2015) Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study. Arthritis Res Ther 17(1):232. 10.1186/s13075-015-0730-2
7. Verstappen SMM, Jacobs JWG, van der Veen MJ, Heurkens AHM, Schenk Y, ter Borg EJ, Blaauw AAM, Bijlsma JWJ, on the behalf of the Utrecht Rheumatoid Arthritis Cohort study group (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66(11):1443–1449. 10.1136/ard.2007.071092
8. Schipper LG, van Hulst LTC, Grol R, van Riel PLCM, Hulscher MEJL, Fransen J (2010) Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford) 49(11):2154–2164. 10.1093/rheumatology/keq195
9. Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Broeder AAD, Riel P, Fransen J, van de Laar MAFJ (2012) A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch rheumatoid arthritis monitoring registry. Ann Rheum Dis 71(6):845–850. 10.1136/annrheumdis-2011-200274
10. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JWJ, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JMW, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PLCM, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73(3):492–509. 10.1136/annrheumdis-2013-204573
11. Smolen JS, Breedveld FC, Burmester GR, et al (2015) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 3–15. doi: 10.1136/annrheumdis-2015-207524
12. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St.Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68(1):1–26. 10.1002/art.39480
13. van Hulst LTC, Hulscher MEJL, van Riel PLCM (2011) Achieving tight control in rheumatoid arthritis. Rheumatology 50(10):1729–1731. 10.1093/rheumatology/ker325
14. Pincus T, Castrejón I, Bergman MJ, Yazici Y (2012) Treat-to-target: not as simple as it appears. Clin Exp Rheumatol 30
15. Vermeer M, Kuper HH, Moens HJB, Drossaers-Bakker KW, van der Bijl AE, van Riel PLCM, van de Laar MAFJ (2013) Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch rheumatoid arthritis monitoring remission induction cohort. Arthritis Care Res (Hoboken) 65(8):1219–1226. 10.1002/acr.21984
16. Vermeer M, Kuper HH, Bernelot Moens HJ, Hoekstra M, Posthumus MD, van Riel PLCM, van de Laar MAFJ (2012) Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. Arthritis Res Ther 14(6):R254. 10.1186/ar4099
17. Mäkinen H, Kautiainen H, Hannonen P, Möttönen T, Leirisalo-Repo M, Laasonen L, Korpela M, Blåfield H, Hakola M, Sokka T (2007) Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol 34(2):316–321
18. Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, Paimela L, Blåfield H, Puolakka K, Möttönen T, FIN-RACo Trial Group (2004) Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 50(7):2072–2081. 10.1002/art.20351
19. Bakker MF, Jacobs JWG, Welsing PMJ, Vreugdenhil SA, van Booma-Frankfort C, Linn-Rasker SP, Ton E, Lafeber FPJG, Bijlsma JWJ, on behalf of the Utrecht Arthritis Cohort Study Group (2011) Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. Ann Rheum Dis 70(6):1099–1103. 10.1136/ard.2010.137943
20. Huizinga T, Nigrovic P, Ruderman E, Schulze-Koops H (2011) The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study: commentary. Int J Adv Rheumatol 9(6):64–1046. 10.1136/ard.2010.141234
21. Sokka T, Pincus T (2003) Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol 30(6):1138–1146
22. Prevoo MLL, Van’T Hof MA, Kuper HH et al (1995) Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44–48. 10.1002/art.1780380107
23. Bruce B, Fries JF The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 23:S14–8
24. Ware JE, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473–483. 10.1097/00005650-199206000-00002
25. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE (2000) Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 43(7):1478–1487. 10.1002/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M
26. van der Heijde D, van der Helm-van Mil AHM, Aletaha D, Bingham CO, Burmester GR, Dougados M, Emery P, Felson D, Knevel R, Kvien TK, Landewé RBM, Lukas C, McInnes I, Silman AJ, Smolen JS, Stanislawska-Biernat E, Zink A, Combe B (2013) EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. Ann Rheum Dis 72(4):479–481. 10.1136/annrheumdis-2012-202779
27. Gossec L, Dougados M, Goupille P, Cantagrel A, Sibilia J, Meyer O, Sany J, Daurès JP, Combe B (2004) Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis 63(6):675–680. 10.1136/ard.2003.010611
28. Kuriya B, Xiong J, Boire G, Haraoui B, Hitchon C, Pope J, Thorne JC, Tin D, Keystone EC, Bykerk V, for the CATCH Investigators, Ahluwalia V, Akhavan P, Arbillaga H, Baron M, Bell M, Bensen W, Boire G, Bykerk V, Cividino A, Colmegna I, Haraoui P, Hitchon C, Jamal S, Keystone E, Klinkhoff A, Kraishi M, Larche M, Lyddell C, Menard H, Mosher D, Nair B, Norris E, Penney C, Pope J, Rubin L, Shaw E, Sutton E, Thorne JC, Zummer M (2014) Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis—results from the Canadian early arthritis cohort (CATCH). J Rheumatol 41(11):2161–2166. 10.3899/jrheum.140137
29. Van Der Woude D, Young A, Jayakumar K et al (2009) Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 60(8):2262–2271. 10.1002/art.24661
30. Klarenbeek NB, van der Kooij SM, Güler-Yüksel M et al (2011) Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 70(2):315–319. 10.1136/ard.2010.136556
31. Van Vollenhoven RF, Severens JL (2011) Observational studies: a valuable source for data on the true value of RA therapies. Clin Rheumatol 30(S1):1–6. 10.1007/s10067-010-1636-7
32. Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, van Essche E, Sileghem A, de Brabanter G, Joly J, Meyfroidt S, van der Elst K, Westhovens R (2015) Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis 74(1):27–34. 10.1136/annrheumdis-2014-205489
33. de Jong PH, Hazes JM, Han HK, Huisman M, van Zeben D, van der Lubbe PA, Gerards AH, van Schaeybroeck B, de Sonnaville PB, van Krugten MV, Luime JJ, Weel AE (2014) Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis 73(7):1331–1339. 10.1136/annrheumdis-2013-204788
34. den Uyl D, ter Wee M, Boers M, Kerstens P, Voskuyl A, Nurmohamed M, Raterman H, van Schaardenburg D, van Dillen N, Dijkmans B, Lems W (2014) A non-inferiority trial of an attenuated combination strategy (‘COBRA-light’) compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis 73(6):1071–1078. 10.1136/annrheumdis-2012-202818
35. van den Broek M, Dirven L, Klarenbeek NB, Molenaar THE, Han KH, Kerstens PJSM, Huizinga TWJ, Dijkmans BAC, Allaart CF (2012) The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study. Ann Rheum Dis 71(2):245–248. 10.1136/annrheumdis-2011-200379
36. Putrik P, Ramiro S, Kvien TK, Sokka T, Uhlig T, Boonen A, Equity in Clinical Eligibility Criteria for RA treatment Working Group (2014) Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country’s wealth? Ann Rheum Dis 73(11):2010–2021. 10.1136/annrheumdis-2013-203819
37. Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJSM, Hazes JMW, Zwinderman AH, Ronday HK, Han KH, Westedt ML, Gerards AH, van Groenendael JHLM, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BAC (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52(11):3381–3390. 10.1002/art.21405